The healthcare landscape is constantly evolving, with Rapid Diagnosis emerging as a cornerstone of effective patient care, particularly in scenarios demanding swift action and immediate results. The recent global health challenges, notably the Coronavirus Disease 2019 (COVID-19) pandemic, have further underscored the critical role of rapid diagnostic tests (RDTs) in managing outbreaks and ensuring timely medical intervention. This article delves into the significance of rapid diagnosis, its applications, and future directions in the realm of modern medicine.
Rapid Diagnostic Tests: A Response to Urgent Needs
The COVID-19 pandemic placed immense pressure on diagnostic capabilities worldwide. The urgent need to identify and isolate individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to an unprecedented surge in demand for diagnostics. To address this, and to minimize exposure to infected individuals, regulatory bodies like the US Food and Drug Administration (FDA) expedited the authorization of numerous RDTs and multiplex panels capable of detecting SARS-CoV-2.
These RDTs include rapid antigen tests and, notably, the first molecular diagnostic tools designed for home use. These advancements empower individuals to collect samples themselves or with caregiver assistance, facilitating convenient and accessible testing. Some home-based test kits are even integrated with smartphone applications, streamlining test interpretation and contributing anonymized data to public health surveillance efforts. It is crucial to note that while these rapid diagnostic kits excel in symptomatic individuals, results obtained from asymptomatic individuals require careful interpretation and should be considered with caution.
Rapid Diagnosis in Travel and Global Health
Beyond pandemic responses, rapid diagnosis is increasingly vital in travel medicine. Individuals falling ill while traveling may seek medical attention in regions with varying healthcare infrastructures. The development and availability of RDTs for diagnosing tropical infectious diseases have expanded significantly, meaning travelers might return home with diagnoses based on tests unfamiliar to their primary healthcare providers.
RDTs for tropical infections predominantly utilize lateral-flow immunochromatographic assays, designed to detect antigens or antibodies related to specific pathogens. It’s important to recognize that only a limited number of these tests, such as for malaria, have received clearance for use in the United States. Consequently, the diagnostic performance characteristics of RDTs utilized overseas may be less familiar to many healthcare professionals in the US. Furthermore, the variety of RDTs available for certain pathogens, like dengue fever, across different countries can exhibit considerable variations in performance, often with limited or poorly documented validation. The inconsistent availability of specific test brands across different institutions further complicates the interpretation of laboratory results obtained abroad.
Here are some common infections where RDTs are frequently employed, illustrating the breadth of their application in rapid diagnosis:
Dengue Fever
Rapid, lateral-flow assays are widely available for dengue fever, capable of detecting the dengue nonstructural protein 1 (NS1) antigen, as well as IgM and IgG antibodies. However, it’s critical to understand that the performance of dengue tests can vary substantially depending on the manufacturer, the specific dengue virus serotypes circulating in a region, a patient’s prior dengue history, and the duration of their symptoms. This variability necessitates careful consideration when interpreting results and selecting appropriate tests.
Emerging Infections
The emergence of new pathogens consistently presents diagnostic challenges. The response to outbreaks of chikungunya, Ebola, and Zika viruses saw the rapid development and deployment of rapid assays. However, the availability and thorough validation of such assays may be limited, particularly during the initial peak of an outbreak when diagnostic tools are most urgently needed. Rapid diagnosis in these situations is crucial for containment and effective public health measures, but the limitations of nascent testing technologies must be acknowledged.
Leishmaniasis
For visceral leishmaniasis, assays designed to detect antibodies against the rK39 antigen have demonstrated strong specificity in endemic regions. These tests exhibit their highest sensitivity for detecting the disease in South Asia, making them valuable tools for rapid diagnosis in these areas.
Leptospirosis
The diagnosis of leptospirosis is complicated by the vast array of pathogenic and intermediate Leptospira serotypes responsible for human disease globally. This serotypic diversity significantly limits the overall usefulness of serologic assays in achieving accurate and rapid diagnosis of leptospirosis.
Malaria
An FDA-cleared RDT for malaria is available and extensively used worldwide. Generally, these tests perform optimally for Plasmodium falciparum infections. However, their performance can be variable or less reliable when detecting other Plasmodium species, highlighting the importance of species-specific considerations in rapid diagnosis of malaria.
Typhoid Fever
Rapid serologic tests for typhoid fever have shown only moderate accuracy in diagnosing the disease. Adding to the complexity, these tests are specifically designed to detect only Salmonella enterica serotype Typhi, limiting their broader diagnostic utility for other Salmonella infections. This specificity is a crucial factor to consider when employing these tests for rapid diagnosis.
The Future Trajectory of Rapid Diagnosis
The range of assays compatible with point-of-care (POC) testing is poised for continued expansion. Building on the diagnostic advancements achieved during the COVID-19 pandemic, the trend toward “at-home” testing, including molecular diagnostics, is expected to grow in the coming years. This expansion will likely encompass both respiratory viruses and a broader spectrum of pathogens.
However, in the context of non-domestic infectious diseases encountered by returning travelers, the practicality of POC testing for a wide array of pathogens may be limited for many healthcare centers. Factors such as test volume, the complexities of personnel training, and cost-effectiveness must be carefully weighed. Despite these challenges, POC testing and rapid diagnosis hold immense promise for common syndromes affecting both travelers and non-travelers, such as respiratory tract and gastrointestinal infections. Rapid diagnosis in these scenarios can significantly inform triage decisions, streamline patient management, and reduce unnecessary laboratory testing, ultimately enhancing the efficiency and effectiveness of healthcare delivery.
References
Babady NE. The FilmArray respiratory panel: an automated, broadly multiplexed molecular test for the rapid and accurate detection of respiratory pathogens. Expert Rev Mol Diagn. 2013;13(8):779–88.
Centers for Disease Control and Prevention. Ready? Set? Test! Patient testing is important. Get the results right. Atlanta: The Centers; 2019. Available from: www.cdc.gov/labquality/images/waived-tests/RST-Booklet_Dec-2019.pdf.
Gonzalez MD, McElvania E. New developments in rapid diagnostic testing for children. Infect Dis Clin North Am. 2018;32(1):19–34.
Hunsperger EA, Yoksan S, Buchy P, Nguyen VC, Sekaran SD, Enria DA, et al. Evaluation of commercially available diagnostic tests for the detection of dengue virus NS1 antigen and anti-dengue virus IgM antibody. PLoS Negl Trop Dis. 2014;8(10):e3171.
Infectious Disease Society of America. IDSA practice guidelines. Available from: www.idsociety.org/practice-guideline/practice-guidelines.
Pai NP, Vadnais C, Denkinger C, Engel N, Pai M. Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries. PLoS Med. 2012;9(9):e1001306.
US Food and Drug Administration. CLIA—Clinical Laboratory Improvement Amendments—currently waived analytes. Available from: www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfClia/analyteswaived.cfm.
US Food and Drug Administration. In vitro diagnostics EUAs. Available from: www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas.
